Enrollment starts for Phase III trials of IBS drug

07/6/2008 | Pharmaceutical Business Review Online

Enrollment has begun in two, 600-subject Phase III trials of rifaximin for treatment of non-constipation irritable bowel syndrome. The studies, which will include 180 sites in Canada and the U.S., will examine how many patients get relief of IBS symptoms for at least two weeks during the first four weeks of a 10-week follow up period after 14 days of receiving rifaximin.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC